Circulating Tumor DNA As a Predictive Biomarker for Treatment Response and Survival in Metastatic Colorectal Cancer

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2024 Dec 16

PMID 39681775

Authors

Mengying Kou

Ying Deng

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the potential of circulating tumor DNA (ctDNA) as a prognostic biomarker to predict treatment response and survival outcomes in patients with metastatic colorectal cancer (mCRC).

Methods: A retrospective analysis was conducted on 134 patients with mCRC who were treated between January 2020 and December 2021. The patients were classified into ctDNA-negative and ctDNA-positive groups based on plasma ctDNA detection. Demographic, clinical, and laboratory parameters, treatment response, survival outcomes, and adverse events were recorded and analyzed.

Results: No significant differences were observed in baseline characteristics between the two groups. Compared to the ctDNA-positive patients, ctDNA-negative patients exhibited superior outcomes, including a higher objective response rate (65.22% vs. 46.15%), disease control rate (81.16% vs. 63.08%), progression-free survival (8.24 ± 1.02 vs. 7.86 ± 0.91 months), overall survival (24.58 ± 3.58 vs. 23.27 ± 3.46 months), and 1-year survival rate (73.91% vs. 55.38%). The ctDNA-positive group had a significantly higher incidence of adverse events. Correlation analyses revealed significant associations between ctDNA status, tumor markers, treatment response, and survival outcomes.

Conclusions: ctDNA is a promising noninvasive biomarker for predicting treatment response, survival, and adverse events in mCRC, potentially guiding personalized therapeutic strategies.

References

Bhimani N, Wong G, Molloy C, Pavlakis N, Diakos C, Clarke S . Cost of treating metastatic colorectal cancer: a systematic review. Public Health. 2022; 211:97-104. DOI: 10.1016/j.puhe.2022.06.022. View

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

Martelli V, Pastorino A, Sobrero A . Prognostic and predictive molecular biomarkers in advanced colorectal cancer. Pharmacol Ther. 2022; 236:108239. DOI: 10.1016/j.pharmthera.2022.108239. View

Schirripa M, Lenz H . Biomarker in Colorectal Cancer. Cancer J. 2016; 22(3):156-64. PMC: 4955946. DOI: 10.1097/PPO.0000000000000190. View

Sudoyo A . A biomarker for metastatic colorectal cancer and treatment goals. Acta Med Indones. 2014; 46(2):81-2. View

Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A . The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs. 2019; 79(13):1375-1394. PMC: 6728290. DOI: 10.1007/s40265-019-01165-2. View

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A . Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022; 72(4):372-401. DOI: 10.3322/caac.21728. View

Leowattana W, Leowattana P, Leowattana T . Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023; 29(10):1569-1588. PMC: 10037252. DOI: 10.3748/wjg.v29.i10.1569. View

10.

Krebs M, Malapelle U, Andre F, Paz-Ares L, Schuler M, Thomas D . Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. JAMA Oncol. 2022; 8(12):1830-1839. DOI: 10.1001/jamaoncol.2022.4457. View

11.

Leers M . Circulating tumor DNA and their added value in molecular oncology. Clin Chem Lab Med. 2019; 58(2):152-161. DOI: 10.1515/cclm-2019-0436. View

12.

Bratman S, Yang S, Iafolla M, Liu Z, Hansen A, Bedard P . Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2022; 1(9):873-881. DOI: 10.1038/s43018-020-0096-5. View

13.

Khan S, Scheffler M, Soomar S, Rashid Y, Moosajee M, Ahmad A . Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. Pathol Res Pract. 2023; 245:154455. DOI: 10.1016/j.prp.2023.154455. View

14.

Piawah S, Venook A . Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019; 125(23):4139-4147. DOI: 10.1002/cncr.32163. View

15.

Shin A, Giancotti F, Rustgi A . Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023; 44(4):222-236. PMC: 10365888. DOI: 10.1016/j.tips.2023.01.003. View

16.

Roschewski M, Rossi D, Kurtz D, Alizadeh A, Wilson W . Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discov. 2022; 3(1):5-15. PMC: 9245363. DOI: 10.1158/2643-3230.BCD-21-0029. View

17.

Wang Y, Song Z, Hu X, Wang H . Circulating tumor DNA analysis for tumor diagnosis. Talanta. 2021; 228:122220. DOI: 10.1016/j.talanta.2021.122220. View

18.

Wei M, Ye M, Dong K, Dong R . Circulating tumor DNA in neuroblastoma. Pediatr Blood Cancer. 2020; 67(10):e28311. DOI: 10.1002/pbc.28311. View

19.

Bonazzi V, Aoude L, Brosda S, Lonie J, Patel K, Bradford J . ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open. 2022; 7(3):100452. PMC: 9271467. DOI: 10.1016/j.esmoop.2022.100452. View

20.

Pessoa L, Heringer M, Ferrer V . ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020; 155:103109. DOI: 10.1016/j.critrevonc.2020.103109. View